Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Falun – page 4

57 clinical trials in Falun, Sweden across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Falun at a glance
57
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

57 trials in Falun

Open in trial search

Plasma cell myeloma

Not recruiting

Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Not recruiting

Study of Belantamab Mafodotin Alone and with Drug Combination for Patients with Relapsed/Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Type 2 diabetes mellitus

Not recruiting

Comparison of dapagliflozin versus metformin treatment in patients with early stage type 2 diabetes to evaluate survival and complications

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin Propanediol
  • Sponsor:Uppsala University

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Heart failure with preserved ejection fraction

Not recruiting

Study of spironolactone and eplerenone in patients with heart failure with preserved ejection fraction (HFpEF)

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Altizide
  • Sponsor:Region Uppsala

Acute myeloid leukaemia

Not recruiting

Study on the Safety and Effectiveness of Adding Hydroxycarbamide to Standard Treatment with Cytarabine and Daunorubicin for Adults with Newly Diagnosed Acute Myeloid Leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Karolinska University Hospital

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Facial paresis

Not recruiting

Study on Betamethasone Sodium Phosphate for Treating Acute Facial Nerve Palsy in Children

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years
  • Sponsor:Region Dalarna

Plasma cell myeloma

Not recruiting

Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Infertility

Not recruiting

Study on Vaginal Progesterone for Improving Live Birth Rates in Women with Infertility Undergoing Frozen/Thawed IVF Natural Cycles

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Progesterone
  • Sponsor:Vaestra Goetalandsregionen

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Rheumatoid arthritis

Not recruiting

Study on the Effectiveness and Tolerability of Oral vs. Subcutaneous Methotrexate for Patients with Early Rheumatoid Arthritis

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Methotrexate
  • Sponsor:Region Vaesterbotten

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Falun

What the registry says about research in the country

01 Oncology Research

Innovative trials exploring treatments for multiple myeloma, breast cancer, and lung cancer. Studies include evaluating novel drug combinations and targeted therapies for better patient outcomes.

  • EGFR-mutated lung cancer treatment optimization
  • Advanced breast cancer endocrine therapy
  • Multiple myeloma treatment combinations

Research focuses on personalized treatment approaches and improved survival rates.

02 Cardiovascular Studies

Clinical trials investigating treatments for atrial fibrillation and cardiovascular disease. Research includes stroke prevention and innovative therapies for vascular conditions.

  • Stroke prevention in atrial fibrillation
  • Abdominal aortic aneurysm management
  • Left ventricular thrombosis treatment

Emphasis on comparing novel anticoagulants with standard treatments.

03 Chronic Disease Management

Studies addressing rheumatoid arthritis, COPD, and other chronic conditions. Research evaluates treatment effectiveness and patient outcomes.

  • Early rheumatoid arthritis therapy optimization
  • COPD treatment strategies
  • Diabetic foot ulcer healing

Focus on improving quality of life and disease management approaches.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.